SEIKAGAKU CORPORATION

Seikagaku Corporation is a pharmaceutical manufacturer and research-driven biotech company headquartered in Tokyo, specializing in glycoscience-based therapeutics. The company develops and manufactures pharmaceutical active ingredients, particularly sodium hyaluronate and chondroitin sulfate ester sodium, used in joint health treatments and medical devices. Core business segments include pharmaceutical APIs (active pharmaceutical ingredients), contract manufacturing/CDMO services for biopharmaceutical partners, and LAL (Limulus Amebocyte Lysate) test reagents for pharmaceutical safety testing. The company maintains robust R&D capabilities in drug development, with regulatory approvals and pipelines in joint injections (SI-449 adhesion prevention material) and other glycoscience-derived therapeutics. Seikagaku operates as a B2B supplier to hospitals, pharmaceutical manufacturers, and clinical research institutions worldwide, with emphasis on regulatory compliance and quality assurance.